NCT07536815 2026-04-17
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
Available
Clinical Trials
25 trialsNCT04085653 2026-04-14
Managed Access Programs for BYL719, Alpelisib
Novartis
Available
NCT05038631 2026-04-13
Managed Access Programs for LEE011, Ribociclib
Novartis
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04313075 2025-07-15
A Compassionate Use Study of Leronlimab in Breast Cancer
CytoDyn, Inc.
No longer available
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT05134922 2025-03-21
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Celcuity Inc
Available
NCT03133988 2025-02-14
Margetuximab Expanded Access Program
TerSera Therapeutics LLC
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT03763604 2024-12-16
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT04395508 2022-07-05
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Genentech, Inc.
Approved for marketing
NCT03123211 2022-05-24
Expanded Access to Veliparib
AbbVie
No longer available
NCT05108740 2021-12-09
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
Novartis
No longer available
NCT04320693 2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing
NCT03706573 2021-07-19
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
Novartis
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02142868 2018-12-21
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Pfizer
No longer available
NCT03067935 2018-05-21
Individual Patient Expanded Access-Glembatumumab Vedotin
Celldex Therapeutics
No longer available
NCT02792725 2017-10-31
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT01120561 2017-02-15
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
No longer available
NCT00338247 2016-04-06
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Novartis
Approved for marketing
NCT01240421 2015-05-22
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Eisai Inc.
Approved for marketing
NCT01130259 2013-09-17
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Sanofi
No longer available